Orchard Healthcare Research Inc. | Skokie, IL

Research site

(Unclaimed)

Location

9711 Skokie Boulevard Suite B, Skokie, Illinois, United States of America

Site insights

Top conditions

Top treatments

Pembrolizumab

Sacituzumab

Lenalidomide

Capecitabine

CB-839

Magrolimab

Palonosetron

Docetaxel

Azacitidine

Neratinib

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

26 of 54 total trials

A Phase 3 Study of Rusfertide in Patients With Polycythemia Vera (VERIFY)

The study is designed to evaluate the safety and efficacy of rusfertide in subjects with polycythemia vera (PV) in maintaining hematocrit control and...

Active, not recruiting

Polycythemia Vera

Drug: Placebo

Drug: Rusfertide

A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)

This study will enroll adult participants with early-stage (stage II-IIIB) non-small cell lung cancer for whom surgery is planned.The aim is to find...

Enrolling

Non-Small Cell Lung Cancer

Drug: Cemiplimab

Drug: REGN7075

A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)

This study is to assess the pharmacokinetics (PK) and safety of SC MK-3475A vs intravenous (IV) pembrolizumab, administered with chemotherapy in firs...

Active, not recruiting

Metastatic Non-small Cell Lung Cancer

Biological: Pembrolizumab

Drug: Nab-paclitaxel

A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell Malignancies

This is a Phase I/II, multicenter, open-label study to evaluate the safety, efficacy, tolerability, and pharmacokinetics of a novel BTK inhibitor, Or...

Active, not recruiting

Part 2：B-cell Malignancies

Part 1：r/r B-cell Malignancies

Drug: Orelabrutinib (ICP-022)

A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)

This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXD) in the following tumor types: endometrial cancer (EC); head...

Enrolling

Recurrent or Metastatic Solid Tumors

Drug: Ifinatamab deruxtecan

A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

The primary objectives of the study are: (1) in the dose-escalation part: to evaluate safety and tolerability and to determine the recommended Phase...

Enrolling

Solid Tumor

Drug: Prednisone

Drug: Farletuzumab ecteribulin

Locations recently updated

A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment

The purpose of this study is to learn about the safety and how effective the study medicine (PF-07220060) plus fulvestrant is compared to the study d...

Enrolling

Advanced or Metastatic Breast Cancer

Drug: Everolimus

Drug: Fulvestrant

Buccal Film vs IV Palonosetron for Prevention of CINV in Cancer Patients Receiving MEC

The phase 3 study is to compare the efficacy and safety of palonosetron, a long-acting 5-HT3 receptor antagonist, by buccal film delivery compared to...

Enrolling

Chemotherapy-induced Nausea and Vomiting

Drug: Palonosetron HCl Buccal Film 0.5 mg

Drug: IV Palonosetron 0.25 mg

Locations recently updated

ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions

The purpose of the study is to compare the efficacy and safety of Luspatercept vs epoetin alfa in the treatment of anemia in adults due to IPSS-R ver...

Enrolling

Myelodysplastic Syndromes

Biological: Epoetin Alfa

Biological: Luspatercept

PALbociclib CoLlaborative Adjuvant Study (PALLAS)

This is a prospective, two arm, international, multicenter, randomized, open-label Phase III study evaluating the addition of 2 years of palbociclib...

Active, not recruiting

Breast Cancer

Drug: Standard Adjuvant Endocrine Therapy

Drug: Palbociclib

Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer (SAPPHIRE)

This study will compare the efficacy of the investigational agent sitravatinib in combination with nivolumab versus docetaxel in patients with advanc...

Active, not recruiting

Metastatic Non-Squamous Non-Small Cell Lung Cancer

Drug: Sitravatinib

Drug: Docetaxel

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

This is a randomized, open-label study comparing the efficacy and safety of adjuvant sacituzumab tirumotecan (sac-TMT; MK-2870) in combination with p...

Enrolling

Triple-Negative Breast Cancer

Biological: sac-TMT

Biological: Pembrolizumab

Locations recently updated

Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy

This study is a Phase II, multi-site, randomized, open-label clinical study to evaluate the safety, efficacy, and pharmacokinetics (PK) of BNT327 at...

Enrolling

Locally Advanced Breast Cancer

Triple Negative Breast Cancer

Drug: BNT327 Dose Level 1 (DL2)

Drug: Antimetabolite

Study of ADI-PEG 20, Venetoclax and Azacitidine in Acute Myeloid Leukemia

Pegylated arginine deiminase (ADI-PEG 20) will be combined with venetoclax and azacitidine for treatment of subjects with previously treated or untre...

Enrolling

Acute Myeloid Leukemia, Adult

Drug: ADI-PEG 20

Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast Cancer (ELEVATE TNBC)

The goals of this clinical study are to learn about the safety, tolerability, dosing and effectiveness of magrolimab in combination with nab-paclitax...

Active, not recruiting

Triple-Negative Breast Cancer

Drug: Sacituzumab Govitecan-hziy

Drug: Magrolimab

Study of Magrolimab in Patients With Solid Tumors (ELEVATELung&UC)

The goals of this clinical study are to learn about the safety, tolerability, dosing and effectiveness of magrolimab in combination with docetaxel in...

Active, not recruiting

Solid Tumor

Drug: Docetaxel

Drug: Magrolimab

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)

The safety and efficacy of pembrolizumab plus the investigator's choice of chemotherapy will be assessed compared to placebo plus the investigator's...

Active, not recruiting

Breast Neoplasms

Drug: dextrose

Drug: liposomal doxorubicin

Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)

The purpose of this study is to evaluate the efficacy and safety of pembrolizumab (MK-3475) plus chemotherapy vs placebo plus chemotherapy as neoadju...

Active, not recruiting

Triple Negative Breast Neoplasms

Biological: Granulocyte colony stimulating factor: Filgrastim or Pegfilgastrim

Drug: Cyclophosphamide

Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)

The purpose of this study is to assess the efficacy and safety of pembrolizumab (MK-3475) versus placebo in combination with neoadjuvant (pre-surgery...

Active, not recruiting

Breast Cancer

Biological: Pembrolizumab (K)

Radiation: Radiation therapy